Treatment options of AIDS-related lymphoma

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 8, 2003, Pages 1331-1343

  Schmidt Wolf, Ingo G H ^a,b   Rockstroh, Jürgen K ^b   Schlegel, Uwe ^b   Pels, Hendrik ^b   Mey, Ulrich ^b   Strehl, John ^b   Weiss, Rudolf ^c   Huhn, Dieter ^d  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c Onkologische Schwerpunktpraxis   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

AIDS; HAART; Lymphoma; Primary CNS lymphoma

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ASPARAGINASE; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IFOSFAMIDE; INDINAVIR; LAMIVUDINE; METHOTREXATE; MITOXANTRONE; NUCLEOSIDE ANALOG; PREDNIMUSTINE; PREDNISONE; PROTEINASE INHIBITOR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; VINCRISTINE; VINDESINE; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; AIDS RELATED COMPLEX; ANEMIA; AREA UNDER THE CURVE; B CELL LYMPHOMA; BONE MARROW TOXICITY; BRAIN LYMPHOMA; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERABILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERBILIRUBINEMIA; LIVER DYSFUNCTION; LOW DRUG DOSE; LYMPHOMA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; REVIEW;

ANTINEOPLASTIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; HYDROXYUREA; IMMUNOTHERAPY; LYMPHOMA, AIDS-RELATED; STEM CELL TRANSPLANTATION;

EID: 0041633592     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.8.1331     Document Type: Review

References (75)

1. AMMASSARI A, CINGOLANI A, PEZZOTTI P et al.: AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology (2000) 55:1194-1200.
2. ANTINORI A, CINGOLANI A, ALBA L et al.: Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS (2001) 15:1483-1491.
3. ANTINORI A, DE ROSSI G, AMMASSARI A et al.: Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J. Clin. Oncol. (1999) 17:554-560.
4. BAIOCCHI OC, COLLEONI GW, NAVAJAS EV et al.: Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma. Acta Oncol. (2002) 41(2):192-196.
5. BESSON C, GOUBAR A, GABARRE J et al.: Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood (2001) 96(8):2339-2344.
6. CHAMBERLAIN MC: Long survival in patients with AIDS-related primary CNS lymphoma. Cancer (1994) 73:1728-1730.
7. COIFFIER B, HAIOUN C, KETTERER N et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood (1998) 92(6):1927-1932.
8. COIFFIER B, LEPAGE E, BRIERE J et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. (2002) 346(4):235-242.
9. CONTU L, LA NASA G, ARRAS M et al.: Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS. Bone Marrow Transplant. (1993) 12:669-671.
10. DAL MASO L, FRANCESCHI S: Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol. (2003) 4:110-119.
11. DONAHUE BR, SULLIVAN JW, COOPER JS: Additional experience with empiric radiotherapy for presumed human immunodeficiency virus-associated primary central nervous system lymphoma. Cancer (1995) 76:328-332.
12. FISHER RI, GAYNOR ER, DAHLBERG S et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin lymphoma. N. Engl. J. Med. (1993) 328(14):1002-1006.
13. FORSYTH PA, YAHOLOM J, DE ANGELIS LM: Combined modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology (1994) 44:1473-1478.
14. GASTALDI R, MARTINO P, GENTILE G et al.: High dose of idarubicin-based regimen for diffuse large cell AIDS-related NHL patients: a pilot study. Haematologica (2001) 86(10):1051-1059.
15. GERARD L, GALICIER L, MALLARD A et al.: Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV-replication: persistent occurrence but improved survival. J. Acquir. Immune Def. Syndr. (2002) 30:478-484.
16. GILL PS, LEVINE AM, KRAILO M et al.: AIDS-related malignant lymphoma: results of prospective treatment trials. J. Clin. Oncol. (1987) 5:1322-1328.
17. GISSELBRECHT C, OKSENJENDLER E, TIRELLI U et al.: Non-Hodgkin lymphoma associated with human immunodeficiency virus: Treatment with LNH 84 regimen in a selected group of patients. Leukemia (1992) 6(3):10-11.
18. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus infected adults. International Collaboration of HIV and Cancer. J. Natl. Cancer Inst. (2000) 92:1823-1830.
19. HOFFMANN C, TABRIZIAN S, WOLF E et al.: Survival of AIDS-patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS (2002) 16:1195-1196.
20. HOFFMANN C, TAPRIZIAN S, WOLF E et al.: Survival of AIDS patients with primary central nervous system lymphoma (PCNSL) is dramatically improved by HAART-induced immune recovery. AIDS (2001) 15(16):2119-2127.
21. HSU FJ, CASPAR CB, CZERWINSKI D et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood (1997) 89(9):3129-3135.
22. HUHN D: HIV-assoziierte Lymphome. In: Internistische Onkologie, (2nd edn.) Wilmanns W, Huhn D, Wilms K (Eds), Stuttgart, Thieme (2000):429.
23. HUZICKA I: Could bone marrow transplantation cure AIDS?: review. Med. Hypotheses (1999) 52(3):247-257.
24. INUNGU J, MELENDEZ MF, MONTGOMERY JP: AIDS-related primary brain lymphoma in Michigan, January 1990 to December 2000. AIDS Patient Care STDS (2002) 16:107-112.
25. IVES NJ, GAZZARD BE, EASTERBROOK PJ: The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J. Infect. (2001) 42:134-139.
26. KANG EM, DE WITTE M, MALECH H et al.: Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. Blood (2002) 99(2):698-701.
27. KAPLAN LD, STRAUS DJ, TESTA MA et al.: Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N. Engl. J. Med. (1997) 336:1641-1648.
28. KERSTEN MJ, KLEIN MR, HOLWERDA AM et al.: Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin lymphoma. J. Clin. Invest. (1997) 99:1525-1533.
29. KIRK O, PEDERSEN C, COZZI-LEPRI A et al.: Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 98(12):3406-3412.
30. LEVINE AM: Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin. Oncol. (2000) 27:442-453.
31. LEVINE AM, SENEVIRATNE L, ESPINA BM et al.: Evolving characteristics of AIDS-related lymphoma. Blood (2000) 96:4084-4090.
32. LEVINE AM, SENEVIRATNE L, TULPULE A: Incidence and management of AIDS-related lymphoma. Oncology (Huntingt.) (2001) 15(5):629-639.
33. LEVINE AM, WERNZ JC, KAPLAN L et al.: Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial. JAMA (1991) 266:84-88.
34. LITTLE RF, PITTALUGA S, GRANT N et al.: Highly effective treatment of AIDS related lymphoma with dose-adjusted EPOCH: Impact of antiretroviral therapy suspension and tumor biology. Blood (2003) 101(12):4653-4659.
35. LITTLE RF, PEARSON D, FRANCHINI G: Dose adjusted EPOCH chemotherapy in previously untreated HIV-associated non-Hodgkin lymphoma: preliminary report to efficacy, immune reconstitution, and HIV control following therapy. Third National AIDS Malignancy Conference, Bethesda, MD. J. AIDS (1999) 21:A33 (Abstract 93).
36. LORI F, MALYHK A, CARA A et al.: Hydroxyurea as an inhibitor of Human Immunodeficiency Virus-Type 1 replication. Science (1994) 266:801-805.
37. MITROU PS, SERKE M, POHL C et al.: Malignes Lymphom assoziiert mit HIV Infektion. Deutsche Medizinische Wochenschr (1991) 116:1217-1223.
38. MOLINA A, KRISHNAN AY, NADEMANEE A et al.: High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer (2000) 89(3):680-689.
39. MURDACA G, CAMPEELLI A, SETTI M et al.: Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. AIDS (2002) 16:304-305.
40. O'DONNELL RT, LEIGH BR, CHRISTENSEN SD et al.: Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma. Cancer Biother. Radiopharm. (1999) 14:167-176.
41. OERTEL SH, RUHNKE MS, ANAGNOSTOPOULOS I et al.: Treatment of Epstein-Barr virus-induced post-transplantation lymphoproliferative disorder with foscarnet alone in an adult after simultaneous heart and renal transplantation. Transplantation (1999) 67(5):765-767.
42. OTIENO MW, BANURA C, KATONGOLE-MBIDDE E et al.: Therapeutic challenges of AIDS-related non-Hodgkin lymphoma in the United States and East Africa. J. Natl. Cancer Inst. (2002) May 15;94(10):718-732.
43. PALELLA FJ Jr, DELANEY KM, MOORMAN AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. (1998) 338:853-860.
44. PORCU P, CALIGIURI MA: Acquired immunodeficiency syndrome-related lymphomas: future directions. Semin. Oncol. (2000) 27:454-462.
45. RAEZ LE, PATEL P, FEUN L et al.: Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL). Crit. Rev. Oncog. (1998) 9:199-208.
46. RAMQVIST T, MAGNUSSON KP, WANG Y, SZEKELY L, KLEIN G, WIMAN KG: Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene (1993) 8(6):1495-1500.
47. RATNER L, LEE J, TANG S et al.: The AIDS Malignancy Consortium: chemotherapy for human immunodeficiency virus associated non-Hodgkin lymphoma in combination with highly active antiretroviral therapy. J. Clin. Oncol. (2001) 19:2171-2178.
48. REMICK SC, MCSHARRY JJ, WOLF BC et al.: Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma. J. Clin. Oncol. (1993) 11:1691-1702.
49. REMICK SC, SEDRANSK N, HAASE RF et al.: Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up. Am. J. Hematol. (2001) 66(3):178-188.
50. SACKTOR N, LYLES RH, SKOLASKY R et al.: HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study; 1990 - 1998. Neurology (2001) 56:257-260.
51. SCHLEGEL U, SCHMIDT-WOLF IGH, DECKERT M: Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. J. Neurol. Sci. (2000) 181:1-12.
52. SCHMIDT-WOLF IGH, ROCKSTROH JK, SCHLEGEL U et al.: New aspects in the treatment of AIDS-related lymphoma. Eur. J. Med. Res. (2002) 7(7):295-303.
53. SCHNEIDER U, RUHNKE M, DELECLUSE HJ et al.: Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with aquired immunodeficiency syndrome during therapy with foscarnet. Ann. Hematol. (2000) 79:214-216.
54. SCHNEIDER U, RUHNKE M, DELECLUSE HJ et al.: Treatment of EBV-associated lymphoproliferative disorders in HIV-infected patients with foscarnet. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1997) 14:97.
55. SLOBOD KS, TAYLOR GH, SANDLUND JT et al.: Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet (2000) Oct 28;356(9240):1493-1494.
56. SMALLEY RV, ANDERSEN JW, HAWKINS MJ et al.: Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin lymphoma. N. Engl J. Med. (1992) 327(19):1336-1341.
57. SPARANO JA, WIERNIK PH, HU X, et al.: Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin lymphoma. J. Clin. Oncol. (1996) 14:3026-3035.
58. SPARANO JA, WIERNIK PH, STRACK M et al.: Infusional cyclophosphamide, doxorubicin and etoposide in HIV-Related non-Hodgkin lymphoma: a follow-up report of a highly active regimen. Leuk. Lymphoma (1994) 14:263-271.
59. SPINA M, GABARRE J, ROSSI G et al.: Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood (2002) 100(6):1984-1988.
60. SPINA M, SPARANO JA, JAEGER U et al.: Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin lymphoma and HIV infection. AIDS (2003) 17(1):137-138.
61. TIRELLI U, ERRANTE D, DOLCETTI R et al.: Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J. Clin. Oncol. (1995) 13(7):1758-1767.
62. TIRELLI U, ERRANTE D, SPINA M et al.: Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. Cancer (1996) 77:2127-2131.
63. TIRELLI U, SPINA M, JAEGER U et al.: Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a Phase I/II study. Recent Results Cancer Res. (2002) 159:149-153.
64. TOSSING G: New developments in interferon therapy. Eur. J. Med. Res. (2001) 6(2):47-65.
65. TULPULE A, LEVINE A: AIDS-related lymphoma. Blood Rev. (1999) 13:147-150.
66. TURTURRO F, HEINEKE HL, DREVYANKO, TF et al.: Adenovirus-p53-mediated gene therapy of anaplastic large cell lymphoma with t(2;5) in a nude mouse model. Gene Ther. (2000) 7(11):930-933.
67. TURTURRO F, SETH P, LINK CJ Jr: In vitro adenoviral vector p53-mediated transduction and killing correlates with expression of coxsackie-adenovirus receptor and alpha(nu)beta5 integrin in SUDHL-1 cells derived from anaplastic large-cell lymphoma. Clin. Cancer Res. (2000) 6(1):185-192.
68. VACCHER E, SPINA M, DI GENNARO G et al.: Concomitant cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma. Cancer (2001) 91:155-163.
69. WEISS R: Behandlung HIV-assoziierter Lymphome. Vorteil durch IFN-alpha? Ecomed-Verlagsgesellschaft AG & Co. KG, Landsberg, Germany (1999):124-127.
70. WEISS R, GÖLKEL L, ARASTEH K et al.: HIV-related lymphoma: Rituximab concomitant to second-line chemotherapy following tumor progression under CHOP or early relapse. Blood (2001) 98(11) (Suppl. 2):253b.
71. WEISS R, HUHN D, MITROU P et al.: HIV-related non-Hodgkin's lymphoma: CHOP induction therapy and interferon-alpha-2b/zidovudine maintenance therapy. Leuk. Lymphoma (1998) 29:103-118.
72. WEISS R, MITROU P, ARASTEH K et al.: HIV-related lymphoma: changes in immune parameters and viral load during chemotherapy. Blood (2000) 96(11):134a.
73. WIERNIK PH: Treatment of human immunodeficiency virus-related lymphoma. Semin. Hematol. (2001) Oct;38(4 Suppl. 10):27-31.
74. WILDE JT, LEE CA, DARBY SC et al.: UK Haemophilia Center Doctor's Organisation: the incidence of lymphoma in the UK haemophilia population between 1978 and 1999. AIDS (2002) 16:1803-1807.
75. WUNDERLICH A, KLOESS M, REISER M et al.: Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann. Oncol. (2003) 14(6):881-893.